Latrodectus mactans Polypeptides for Erectile Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for erectile dysfunction, such as PDE-5 inhibitors, are not effective for all patients and come with side effects, and there is a need for safe and effective alternative therapies.
Innovation Solution
The use of polypeptides isolated from the venom of the Chilean spider Latrodectus mactans, specifically biologically active fragments or variants thereof, which can be formulated into pharmaceutical compositions for administration to treat erectile dysfunction by promoting smooth muscle relaxation in the corpus cavernosum.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE-5 inhibitors are used to treat erectile dysfunction, then erectile function is improved, but side effects occur and effectiveness is reduced in refractile patients
Solution Approach 1:
The patent converts the harmful neurotoxic effects of latrotoxin (which cause muscle contraction and pain) into a beneficial therapeutic effect by using a modified peptide sequence that selectively relaxes smooth muscle in the corpus cavernosum. The natural toxin's mechanism is inverted to achieve erection rather than contraction, transforming a harmful substance into a useful medication.
Solution Approach 2:
The patent modifies the amino acid sequence of latrotoxin to create a peptide with different pharmacological properties. By changing specific amino acid residues (e.g., positions 1-6 sequence modification), the peptide loses neurotoxicity while retaining smooth muscle relaxation activity, thereby changing the parameter of biological activity to achieve therapeutic effect without side effects.
2Reliability
If standard PDE-5 inhibitor treatments are used, then some patients achieve erection, but 30% of patients are refractile to treatment
Solution Approach 1:
The patent creates a new therapeutic mechanism by copying the smooth muscle relaxation effect of natural latrotoxin through a modified peptide sequence. This alternative mechanism bypasses the PDE-5 inhibition pathway, potentially effective in patients who are refractile to standard PDE-5 inhibitors, thereby expanding adaptability across different patient populations.
3Reliability
If PDE-5 inhibitors are administered, then erectile dysfunction is treated, but contraindications arise with certain medications and conditions
Solution Approach 1:
The patent eliminates the harmful interaction between PDE-5 inhibitors and nitrates/anticoagulants by using a completely different mechanism of action. The modified latrotoxin peptide directly relaxes smooth muscle without affecting PDE-5 enzymes, thereby removing the contraindication while maintaining treatment efficacy for erectile dysfunction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively induce smooth muscle relaxation, potentially offering a safer and more effective treatment option for erectile dysfunction, with the potential for synergistic effects when combined with existing therapies like sildenafil citrate.
Implementation Method 1
The polypeptides effectively induce smooth muscle relaxation, potentially offering a safer and more effective treatment option for erectile dysfunction
Data Source
AI summary
The present invention features compositions and methods for the treatment of erectile dysfunction. The compositions include substantially pure polypeptides derived from α-latrotoxin and can include other substances, such as pharmaceutically acceptable carriers or diluents, liposomes, hydrogels, and additional active ingredients for the treatment of erectile dysfunction. Also provided are methods, including methods for using the compositions for treatment of erectile dysfunction and in the preparation of medicaments.